Vir Biotechnology Inc. (VIR) Misses Q2 EPS by 10c, provides guidance

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q2 EPS of ($0.80), $0.10 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $1.21 million versus the consensus estimate of $2.66 million.

2025 Financial Guidance

Based on current operating plans, the Company expects its cash, cash equivalents and investments to fund operations into mid-2027.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• CrowdStrike Holdings Inc. (CRWD) Tops Q1 EPS by 3c, Offers Guidance
• Genco Shipping urges shareholders to reject Diana's $24.80 takeover bid